The condition that affects 5 million Americans, gets misdiagnosed for years, and is routinely undertreated — until it's too late to avoid surgery.
Dupuytren's contracture is a slow tightening of the tissue under the skin of your palm. Over months and years it pulls one or more fingers down toward the palm so they can't fully straighten.
Just under the skin of your palm is a thin, tough sheet of connective tissue called the palmar fascia. Its normal job is to anchor the skin so your grip doesn't slide around. You never think about it. In Dupuytren's, this sheet turns against you.
For reasons rooted in your genes, cells in the fascia called myofibroblasts switch into overdrive. They lay down excess collagen and they contract — the same machinery your body uses to close a wound, except here there is no wound to close. The fascia thickens, shortens and pulls. (Rayan 2007)
The first thing most people notice is a nodule — a firm lump in the palm, often near the base of the ring or little finger. It can feel like a callus you can't rub away. It is usually painless. People ignore it for years.
Over time the nodule's tissue organises into a cord — a rope-like band of contracted collagen that runs along the line of the old fascia, up into the finger. The cord is the villain. As it shortens it behaves like a guitar string winding tighter, bending the knuckle (MCP joint) and then the middle finger joint (PIP joint) into a fixed bend.
This is the key distinction your doctor may not spell out: a cord is not a tendon. Your tendons are fine. The problem is a separate, diseased structure sitting on top of them — which is exactly why the fix is to release or remove the cord, not to repair anything inside the finger.
The contracting cell, the myofibroblast, is driven by signalling chemicals (TGF-β among them) and by mechanical tension. Tension feeds the disease: the tighter the cord pulls, the more the cells are told to keep contracting. That feedback loop is why Dupuytren's tends to be a one-way street, and why catching it early matters.
It does not advance at a steady pace. It moves in bursts and plateaus — quiet for a year, then noticeably worse over a few months. That unpredictability is one reason "let's just watch it" feels reassuring and is so often the wrong call.
Dupuytren's is one of the most heritable common conditions in medicine. It also hides in plain sight in millions of people who are told they don't fit the picture.
This is not a "wear and tear" condition you brought on yourself. The landmark genetic study identified that susceptibility clusters in the WNT signalling pathway — the same developmental machinery that governs how connective tissue forms. (Dolmans 2011) A later genome-wide association study expanded this to 26 risk loci implicated in fibrosis. (Ng 2017)
Practically, that means: if a parent or sibling has it, your odds are meaningfully higher. Strong family history, onset before 50, disease on both hands, and lumps elsewhere (knuckle pads, soles of the feet, the penis) together make up what's called the Dupuytren diathesis — a marker of aggressive disease and high recurrence.
"Viking disease" captures that prevalence is highest in people of Northern European descent. (Hindocha 2009) But the label has hardened into a stereotype that gets people misdiagnosed:
Globally the affected population runs into the tens of millions. The honest statement is that we do not have good prevalence data outside white European cohorts — and absence of data has been wrongly read as absence of disease.
Note what this list means: you can do everything right and still get it. The genes load the gun.
Surgeons grade Dupuytren's by the total flexion deformity of a finger — how far short of straight it sits. This single number drives almost every treatment decision, so it's worth understanding precisely.
The angle is measured with a goniometer and is the sum of the deficits at the knuckle (MCP joint) and the middle finger joint (PIP joint). A quick home check is the tabletop test: lay your palm flat on a table. If the finger won't lie flat, you have a measurable contracture — and it's time to be seen.
The lesson hidden in this scale: every stage you wait makes the next treatment bigger, riskier and less complete. Stage is not just a label — it's a clock.
There are five real options. None cures the underlying biology — every one is mechanical, and every one can recur. A good clinician walks you through all five. Many present only the one they personally perform.
The most commonly prescribed plan, and the one to question hardest. For a stable stage 0–1 hand, monitoring is reasonable. But "watch and wait" is frequently used as a substitute for action while a contracture quietly crosses the line past which it can be fully corrected. Waiting is a decision, not a neutral default — and it should come with a re-measurement date, not a vague "come back if it gets worse."
A fine needle is used to repeatedly perforate and weaken the cord under local anaesthetic until it snaps and the finger straightens. No incision, recovery in days, and it can be repeated. In skilled hands it is elegant and low-risk; the technique was refined into an art by clinicians like Eaton and Badois/Lermusiaux in France.
The honest trade-off is durability. In a five-year randomised trial, recurrence after needle fasciotomy was about 85%, versus roughly 21% after open surgery. (van Rijssen 2012) It buys years, not permanence — which is fine if you understand that going in.
Recurrence ≈ 50–85% at 5 yrsIn-office, days to recoverCollagenase clostridium histolyticum is an enzyme injected directly into the cord to dissolve its collagen; the next day the clinician manipulates the finger straight. It works (Hurst 2009, NEJM) and avoids a scalpel — but it is a $1,000+ drug per cord, frequently denied or only partly covered by insurance.
Durability is similar to needle release: roughly 47% recurrence at five years. (Peimer 2015, CORDLESS) And access has gone backwards — the manufacturer withdrew the product (Xiapex) from European markets in 2020 for commercial, not safety, reasons, stranding patients who relied on it.
Recurrence ≈ 47% at 5 yrs$1,000+ per cordThe diseased cord and fascia are surgically cut out. Variants escalate in size and durability: partial (limited) fasciectomy removes the visibly diseased tissue; dermofasciectomy removes the overlying skin too and replaces it with a graft, and has the lowest recurrence of any option. Recovery runs weeks to months with hand therapy.
This is where the stakes are highest, and where the consent conversation too often glosses over what can go wrong. Surgery can restore a hand — and it can leave one worse than before. These risks are real, not theoretical:
Recurrence ≈ 20–50% at 10 yrsWeeks–months recoveryLow-dose radiotherapy to active nodules in early disease (stage 0–1) has evidence for slowing or halting progression. (Betz 2010) It is standard in parts of Germany and almost never offered in the US and UK — partly because it only helps before a contracture forms, which is exactly the stage at which patients are told to "wait." It cannot reverse an established contracture.
The pattern to notice: the one option that works early is the one almost no one is offered early.
Dupuytren's is not cured by any current treatment. It is managed. Every option releases the cord that is there now; none stops your biology from building another. Anyone who tells you a procedure is permanent is selling, not informing.
| Treatment | Recurrence | Window | Source |
|---|---|---|---|
| Needle aponeurotomy | ~85% | 5 years | van Rijssen 2012 |
| Collagenase (Xiaflex) | ~47% | 5 years | Peimer 2015 |
| Limited fasciectomy | ~21% | 5 years | van Rijssen 2012 |
| Fasciectomy (broad estimate) | 20–50% | 10 years | Rayan 2007 |
| Dermofasciectomy | Lowest | 10 years | highest-risk surgery |
Here is something genuinely uncertain, so we'll say it plainly: the field cannot agree on what "recurrence" means. Is it any return of a cord? A 20-degree increase in angle? A return that crosses a treated joint? Studies use different definitions, which is why you'll see the same treatment quoted at wildly different rates. A 2014 international Delphi panel tried to standardise it and proposed more than 20 degrees of contracture at one year in a previously treated finger — but it is not universally used. (Felici 2014)
What recurrence means for you is simpler and harsher: another procedure, on tissue that is now scarred from the last one, with higher risk and a worse result each time. The strategy that minimises lifetime procedures is not always the one your first specialist recommends.
"Choose your first treatment as if there will be a second and a third — because for most people, there will be."
Most hand surgeons are skilled and well-meaning. The failures here are structural — built into how the specialty is trained, paid and time-limited — and patients pay for them.
Surgery is sometimes presented as the definitive answer when a needle release or collagenase would have bought years at a fraction of the risk. A scalpel as a first move for a moderate, single-cord contracture is often more than the situation needs.
Stage 0–1 is treated as "nothing to do yet." But it is the only window where radiotherapy can help and where extension splinting has the most leverage. "Come back when it's worse" trades away your best options.
Many patients are never told NA exists, because their surgeon doesn't perform it. Radiotherapy is routinely omitted in the US and UK. You cannot choose an option you were never offered.
Patients who ask "will it come back?" are too often reassured rather than informed. The data above is rarely volunteered.
Surgeons are paid to operate. That is not an accusation of bad faith — it is a structural fact, and it shapes which option gets recommended when a patient is sitting in a surgical clinic. The honest move is to get the staging measured, then seek a second opinion from someone who offers a different modality before committing to an irreversible one.
Across patient communities, the most repeated regret is not "I waited too long." It is "I let them operate too soon, and now my hand is stiffer than the disease ever made it."
That pattern is drawn from recurring themes in public Dupuytren's patient forums and support groups. It reflects documented sentiment, not any individual's named story.
A few degrees on a goniometer doesn't capture what this does to a life. The hand is how we greet, work, hold and signal. Dupuytren's quietly rewrites all of it.
There is a specific moment most patients describe: the realisation that the hand is not coming back on its own. For people whose identity or income is in their hands — tradespeople, musicians, surgeons, climbers — that lands as grief, not inconvenience.
Anxiety about progression, low mood, and social withdrawal are common and under-acknowledged. The condition is "minor" by the standards of a hospital triage list, which is precisely why the emotional toll goes unspoken in the exam room.
In support groups the same sentence recurs in different words: "It's not the pain. It's that my own hand stopped being mine — and no one took it seriously until it was bad enough to cut."
The isolation is part of the disease. Few people in your life have heard of it. "It's just a bent finger" is the well-meaning dismissal that makes patients stop talking about it — and stop pushing for the early care that actually helps.
Dupuytren's affects millions, has a clear biology and a desperate unmet need. So why is there no real treatment pipeline, no splinting protocol in the guidelines, no progressive extension programme? The answer is economics, not science.
Dupuytren's sits in a funding blind spot. It is rarely fatal, so it scores low on the metrics that allocate research money. National research budgets follow mortality and lobbying power; a non-lethal hand condition in mostly older patients commands neither. The result is decades of near-silence.
Collagenase (Xiaflex) was the first and essentially only drug developed specifically for Dupuytren's. It proved the biology was druggable — and then commercial decisions pulled it from European markets and priced it out of reach for many elsewhere. (see §5) One drug, partially retreating, is the entire pharmaceutical story.
There is evidence that night extension splinting after release helps hold correction and delay recurrence, yet there is no standard progressive splinting protocol in mainstream clinical guidelines, and almost no device designed specifically for how this condition behaves stage by stage. Patients are sent home from a $1,000 injection or major surgery with, at best, a generic off-the-shelf splint and no programme.
The real momentum comes from patients, not industry. The Dupuytren Research Group — a patient-founded non-profit led by hand surgeon Dr Charles Eaton — runs registries and studies that the funding system never prioritised. (dupuytrens.org) That a grassroots foundation carries this much of the field tells you everything about the gap.
It is the same logic that put this page in front of you. When an industry won't build what patients plainly need, a patient eventually builds it — which is exactly why an independent, patient-founded effort is developing the progressive splinting system that the guidelines describe but no company sells.
A progressive extension system designed specifically for how Dupuytren's behaves, stage by stage — by a patient who got tired of waiting for the industry to care.
See the kit system →This page is educational and reflects the published literature plus documented patient-community experience. It is not medical advice and is not a substitute for assessment by a qualified hand specialist. Recurrence figures vary by study because "recurrence" is not consistently defined (see §6). Consult your physician about your individual case.